Table 1 Baseline characteristics of individuals who did and did not develop a recurrent SSTI during the study period
Baseline variable | No recurrent SSTI (n = 55) | Had recurrent SSTI (n = 30) | Total (n = 85) |
|---|---|---|---|
Sex | |||
Male | 30 (65.2 %) | 16 (34.8 %) | 46 (54.1 %) |
Female | 25 (64.1 %) | 14 (35.9 %) | 39 (45.9 %) |
Sexual behavior | |||
Male | 30 (65.2 %) | 16 (34.8 %) | 46 |
Sex with men and women | 6 (75.0 %) | 2 (25.0 %) | 8 (17.4 %) |
Sex with men | 11 (64.7 %) | 6 (35.3 %) | 17 (36.7 %) |
Sex with women | 13 (61.9 %) | 8 (38.1 %) | 21 (45.7 %) |
Female | 25 (64.1 %) | 14 (35.9 %) | 39 |
Sex with women | 1 (100 %) | 0 (0 %) | 1 (2.6 %) |
Sex with men | 24 (63.2 %) | 14 (36.8 %) | 38 (97.4 %) |
Mean initial age (sd) | 40.7 (1.5) | 40.1 (1.9) | 40.5 (1.2) |
Median initial CD4 (IQR) | 363 (180–553) | 351 (242–542) | 353 (199–552) |
Initial VL at time of first SSTI | |||
<1000 | 28 (70.0 %) | 12 (30.0 %) | 40 (47.1 %) |
1000+ | 27 (60.0 %) | 18 (40.0 %) | 45 (52.9 %) |
IVDU history | |||
No | 49 (67.1 %) | 24 (32.9 %) | 73 (86.9 %) |
Yes | 5 (45.4 %) | 6 (54.6 %) | 11 (13.1 %) |
Inhaled drug use | |||
No | 41 (64.1 %) | 23 (35.9 %) | 64 (76.2 %) |
Yes | 13 (65.0 %) | 7 (35.0 %) | 20 (23.8 %) |
Methamphetamine use | |||
No | 54 (65.1 %) | 29 (35.9 %) | 83 (98.8 %) |
Yes | 0 (0 %) | 1 (100 %) | 1 (1.2 %) |
Incarceration | |||
No | 47 (61.8 %) | 29 (38.2 %) | 76 (90.5 %) |
Yes | 7 (87.5 %) | 1 (12.5 %) | 8 (9.5 %) |
Race | |||
African-American | 52 (67.5 %) | 25 (32.5 %) | 77 (91.7 %) |
Caucasian | 2 (40.0 %) | 3 (60.0 %) | 5 (5.9 %) |
Hispanic | 1 (50.0 %) | 1 (50.0 %) | 2 (2.4 %) |
Educational status | |||
Did not complete high school | 5 (83.3 %) | 1 (16.7 %) | 6 (22.2 %) |
High school graduate | 1 (33.3 %) | 2 (66.7 %) | 3 (11.1 %) |
Some college | 8 (66.7 %) | 4 (33.3 %) | 12 (44.4 %) |
College graduate | 4 (66.7 %) | 2 (33.3 %) | 6 (22.2 %) |
Employment during follow-up | |||
No | 32 (64.0 %) | 18 (36.0 %) | 50 (59.5 %) |
Yes | 22 (64.7 %) | 12 (35.3 %) | 34 (40.5 %) |
Chronic skin disease | |||
No | 38 (69.1 % | 17 (30.9 %) | 55 (64.7 %) |
Yes | 17 (56.7 %) | 13 (43.3 %) | 30 (35.3 %) |
Hepatitis C | |||
No | 47 (64.4 %) | 26 (35.6 %) | 73 (85.9 %) |
Yes | 8 (66.7 %) | 4 (33.3 %) | 12 (14.1 %) |
Non-hepatitis liver disease | |||
No | 54 (67.5 %) | 26 (32.5 %) | 80 (94.1 %) |
Yes | 1 (20.0 %) | 4 (80.0 %) | 5 (5.9 %) |
Initial SSTI type | |||
Abscess | 28 (56.0 % | 22 (44.0 %) | 50 (58.8 %) |
Furuncle | 20 (74.1 %) | 7 (25.9 %) | 27 (31.8 %) |
Cellulitis | 7 (87.5 %) | 1 (12.5 %) | 8 (9.4 %) |
Incision and drainage performed | |||
No | 41 (71.9 %) | 16 (28.1 %) | 57 (67.1 %) |
Yes | 14 (50.0 %) | 14 (50.0 %) | 28 (32.9 %) |
Initial SSTI S aureus | |||
No | 48 (68.6 %) | 22 (31.4 %) | 70 (82.4 %) |
Yes | 7 (46.7 %) | 8 (26.7 %) | 15 (17.7 %) |
Initial SSTI MRSA | |||
No | 50 (67.6 %) | 24 (32.4 %) | 74 (87.1 %) |
Yes | 5 (45.5 %) | 6 (54.5 %) | 11 (12.9 %) |
Initial SSTI Treatment | |||
Combination therapy | 11 (55.0 %) | 9 (45.0 %) | 20 (23.5 %) |
Beta-lactam | 12 (60.0 %) | 8 (40.0 %) | 20 (23.5 %) |
Clindamycin | 16 (76.2 %) | 5 (23.8 %) | 21 (24.7 %) |
Fluoroquinolone | 4 (80.0 %) | 1 (20.0 %) | 5 (5.9 %) |
Trimethoprim- sulfamethoxazole | 5 (62.5 %) | 3 (37.5 %) | 8 (9.4 %) |
Vancomycin | 2 (100 %) | 0 (0 %) | 2 (2.3 %) |
None | 3 (100 %) | 0 (0 %) | 3 (3.5 %) |
Unknown | 2 (33.3 %) | 4 (66.7 %) | 6 (7.1 %) |
Chlamydia since 2004 | |||
No | 52 (64.2 %) | 29 (35.8 %) | 81 (95.3 %) |
Yes | 3 (75.0 %) | 1 (25.0 %) | 4 (4.7 %) |
Gonorrhea since 2004 | |||
No | 54 (65.1 %) | 29 (34.9 %) | 83 (97.7 %) |
Yes | 1 (50.0 %) | 1 (50.0 %) | 2 (2.3 %) |
Syphilis since 2004 | |||
No | 50 (63.3 %) | 29 (36.7 %) | 79 (92.9 %) |
Yes | 5 (83.3 %) | 1 (16.7 %) | 6 (7.1 %) |
Human papilloma virus (Clinical) since 2004 | |||
No | 47 (65.3 %) | 25 (34.7 %) | 72 (84.7 %) |
Yes | 8 (61.5 %) | 5 (38.5 %) | 13 (15.3 %) |
Human papilloma virus (Pap) since 2004 | |||
No | 45 (64.3 %) | 25 (35.7 %) | 70 (82.4 %) |
Yes | 10 (66.7 %) | 5 (33.3 %) | 15 (27.6 %) |
Trichomonas since 2004 | |||
No | 47 (61.8 %) | 29 (38.2 %) | 76 (89.4 %) |
Yes | 8 (88.9 % | 1 (11.1 %) | 9 (10.6 %) |
Any sexually transmitted disease since 2004 | |||
No | 29 (59.2 %) | 20 (40.8 %) | 49 (57.7 %) |
Yes | 26 (72.2 %) | 10 (27.8 %) | 36 (42.4 %) |
Pneumocystic jirovecii since 2004 | |||
No | 54 (65.8 %) | 28 (34.2 %) | 82 (96.5 %) |
Yes | 1 (33.3 %) | 2 (66.7 %) | 3 (3.5 %) |
Non-tuberculous mycobacteria since 2004 | |||
No | 53 (63.9 %) | 30 (36.1 %) | 83 (97.7 %) |
Yes | 2 (100.0 %) | 0 (0.0 %) | 2 (2.4 %) |
Cytomegalovirus since 2004 | |||
No | 54 (64.3 %) | 30 (35.7 %) | 84 (98.8 %) |
Yes | 1 (100.0 %) | 0 (0.0 %) | 1 (1.2 %) |
Cryptococcus since 2004 | |||
No | 53 (64.6 %) | 29 (35.4 %) | 82 (96.5 %) |
Yes | 2 (66.7 %) | 1 (33.3 %) | 3 (3.5 %) |
Initial TMP-SMX use | |||
No | 41 (65.1 %) | 22 (34.9 %) | 63 (74.1 %) |
Yes | 14 (63.6 %) | 8 (36.4 %) | 22 (25.9 %) |
Initial azithromycin use | |||
No | 48 (63.2 %) | 28 (36.8 %) | 76 (89.4 %) |
Yes | 7 (77.8 %) | 2 (22.2 %) | 9 (10.6 %) |
Initial HAART use | |||
No | 13 (52.0 %) | 12 (48.0 %) | 25 (29.4 %) |
Yes | 42 (70.0 %) | 18 (30.0 %) | 60 (70.6 %) |
Initial catheter presence | |||
No | 54 (65.9 %) | 28 (34.1 %) | 82 (96.5 %) |
Yes | 1 (33.3 %) | 2 (66.7 %) | 3 (3.5 %) |
Initial insurance Medicaid | |||
No | 16 (64.0 %) | 9 (36.0 %) | 25 (29.4 %) |
Yes | 39 (65.0 %) | 21 (35.0 %) | 60 (70.6 %) |
Initial cancer status | |||
No | 50 (63.3 %) | 29 (36.7 %) | 79 (92.9 %) |
Yes | 5 (83.3 %) | 1 (16.7 %) | 6 (7.1 %) |
Initial diabetes | |||
No | 48 (65.8 %) | 25 (34.3 %) | 73 (85.9 %) |
Yes | 7 (58.3 %) | 5 (41.7 %) | 12 (14.1 %) |
Initial ESRD status | |||
No | 48 (65.8 %) | 25 (34.3 %) | 73 (85.9 %) |
Yes | 7 (58.3 %) | 5 (41.7 %) | 12 (14.1 %) |